1. Wenzel S.E., Schwartz L.B., Langmack E.L. et al. Evidence that severe asthma can be divided pathologically into two inf lammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 1999; 160 (3): 1001-1008. https://doi.org/10.1164/ajrccm.160.3.9812110.
2. Price D.B., Rigazio A., Campbell J.D. et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir. Med. 2015; 3 (11): 849-858. https://doi.org/10.1016/S2213-2600(15)00367-7.
3. de Groot J.C., Storm H., Amelink M. et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016; 2 (2): pii: 00100-2015.4. https://doi.org/10.1183/23120541.00100-2015.
4. Schleich F.N., Chevremont A., Paulus V. et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur. Respir. J. 2014; 44 (1): 97-108. https://doi.org/10.1183/09031936.00201813.
5. Buhl R., Humbert M., Bjermer L. et al. Severe eosinophilic asthma: a roadmap to consensus. Eur. Respir. J. 2017; 49 (5): pii: 1700634. https://doi.org/10.1183/13993003.00634-2017.
6. Chung K.F. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr. Opin. Pulm. Med. 2018; 24 (1): 4-10. https://doi.org/10.1097/MCP.0000000000000434.
7. Pelaia C., Vatrella A., Busceti M.T. et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des. Devel. Ther. 2017; 11: 3137-3144. https://doi.org/10.2147/DDDT.S150656.
8. Haldar P., Brightling C.E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009; 360: 973-984. https://doi.org/10.1056/NEJMoa0808991.
9. Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651-659. https://doi.org/10.1016/S0140-6736(12)60988-X.
10. Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1198-1207. https://doi.org/10.1056/NEJMoa1403290.
11. Bel E.H., Wenzel S.E., Thompson P.J. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1189-1197. https://doi.org/10.1056/NEJMoa1403291.
12. Albers F.C., Price R.G., Smith S.G., Yancey S.W. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J. Allergy Clin. Immunol. 2017; 140 (5): 1464-1466.e4. https://doi.org/10.1016/j.jaci.2017.06.010.
13. Черняк Б.А., Воржева И.И. Эффективность и безопасность меполизумаба при тяжелой эозинофильной астме: обзор литературы. Фарматека. 2019; 11: 10-20. https://doi.org/10.18565/pharmateca.2019.11.10-20.
14. Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin. Ther. 2016; 38 (9): 2058-2070.е1. https://doi.org/10.1016/j.clinthera.2016.07.010.
15. Khatri S., Moore W., Gibson P.G. et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J. Allergy Clin. Immunol. 2019; 143 (5): 1742-1751.е7. https://doi.org/10.1016/j.jaci.2018.09.033.
16. Gevaert P., van Bruaene N., Cattaert T. et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 2011; 128 (5): 989-995.е8. https://doi.org/10.1016/j.jaci.2011.07.056.
17. Bachert C., Sousa A.R., Lund V.J. et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J. Allergy Clin. Immunol. 2017; 140 (4): 1024-1031.е14. https://doi.org/10.1016/j.jaci.2017.05.044.
18. Tuttle K.L., Buchheit K.M., Laidlaw T.M., Cahill K.N. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. Pract. 2018; 6 (3): 1045-1047. https://doi.org/10.1016/j.jaip.2018.01.038.
19. Cavaliere C., Incorvaia C., Frati F. et al. Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps. Clin. Mol. Allergy. 2019; 17: 3. https://doi.org/10.1186/s12948-019-0106-2.
20. Sánchez-Jareño M., Barranco P., Romero D. et al. Severe eosinophilic allergic asthma responsive to mepolizumab after failure of 2 consecutive biologics. J. Investig Allergol. Clin. Immunol. 2019; 29 (1): 79-81. https://doi.org/10.18176/j.iaci.0340.